Prof Bertrand Tombal from Cliniques Universitaires St Luc in Brussels was asked by MediMix to choose noteworthy data from the poster discussion session on prostate cancer. He highlighted two studies that compared PSMA-PET scans to traditional imaging for detecting metastases. Additionally, he delved into the application of PARP inhibitors in mCRPC patients by examining the quality of life results from both the phase III PROpel trial with olaparib + abiraterone and the phase III TALAPRO-2 trial with talazoparib + enzalutamide.
With the educational support of:
